TTMP_BC030499 inhibitors are chemical compounds that exert their inhibitory effects through the modulation of specific signaling pathways. Staurosporine, a broad-spectrum kinase inhibitor, impedes TTMP_BC030499 activity by interfering with the phosphorylation of key proteins, which could be crucial for TTMP_BC030499 signaling. Similarly, LY 294002 and Wortmannin, both PI3K inhibitors, attenuate PI3K pathway signaling, leading to a reduction in the phosphorylation state of proteins associated with TTMP_BC030499, causing a functional downturn in TTMP_BC030499. Rapamycin targets mTOR within the PI3K/AKT/mTOR pathway, hampering the phosphorylation of proteins that either regulate or are regulated by TTMP_BC030499, thus diminishing its activity. MEK inhibitors such as U0126 and PD 98059 disrupt the MAPK/ERK pathway, which, if associated with TTMP_BC030499, results in its functional inhibition. SB 203580's inhibition of p38 MAPK may similarly reduce TTMP_BC030499 activity if it operates downstream or is influencedby this signaling node. SP600125 acts as a JNK pathway inhibitor, which could attenuate TTMP_BC030499's activity by impinging on JNK-mediated signaling mechanisms.
Dasatinib, by inhibiting Src family kinases, has the potential to disrupt signaling cascades that modulate TTMP_BC030499's activity, leading to its functional suppression. Bortezomib, through proteasome inhibition, blocks NF-κB signaling, which can diminish TTMP_BC030499's activity if it is regulated by this pathway. Imatinib, which targets BCR-ABL tyrosine kinase as well as c-Kit and PDGFR, could hinder pathways that activate TTMP_BC030499, thereby reducing its activity. Lastly, Sorafenib, by targeting RAF kinases, suppresses the MAPK/ERK pathway, which would result in the inhibition of TTMP_BC030499 if it is a part of or influenced by this signaling cascade. Collectively, these inhibitors leverage their impacts on critical kinases and signaling pathways to achieve a coordinated downregulation of TTMP_BC030499's functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that indirectly inhibits TTMP_BC030499 by blocking the phosphorylation of proteins that may be required for TTMP_BC030499 signaling or activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that leads to decreased PI3K pathway signaling. The inhibition of this pathway can decrease the phosphorylation status of TTMP_BC030499 or its associated signaling proteins, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway. This inhibition may reduce the phosphorylation and activation of proteins downstream or upstream of TTMP_BC030499, thereby reducing its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that impairs the MAPK/ERK signaling pathway. Inhibition of this pathway could lead to reduced activity of TTMP_BC030499 if it is involved in signaling through MAPK/ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it could diminish the activity of TTMP_BC030499 if TTMP_BC030499 is downstream of or modulated by p38 MAPK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can decrease AKT phosphorylation, potentially leading to reduced activity of TTMP_BC030499 if it is dependent on PI3K/AKT signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is involved in the MAPK/ERK pathway. This could lead to diminished activity of TTMP_BC030499 if it is regulated by the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If TTMP_BC030499 is modulated by JNK signaling, inhibition by SP600125 would lead to a decrease in TTMP_BC030499 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that can inhibit Src family kinases. If TTMP_BC030499 activity is dependent on Src kinase signaling, dasatinib would lead to its functional inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of IκB, thereby inhibiting NF-κB signaling. If TTMP_BC030499 is regulated by NF-κB, bortezomib would decrease its activity. | ||||||